AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.

Also called NCT07697391

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 285 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07697391
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07697391. Randomized; no masking; primary purpose treatment. Start 2026-07-16 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
Acronym
AI-LIFE-T2D-OB
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Behavioral)
AI-Assisted Intensive Lifestyle Intervention
Intervention (Drug)
Tirzepatide
Intervention (Behavioral)
Standard Lifestyle Management
Lead sponsor
The First Affiliated Hospital of Anhui Medical University (class: other)
Collaborator
Zhejiang Nutriease Health Technology Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07697391
Content hash
28690fdd0fe34b6fff60a9ae14e0883e018ab23cb85a27ef049460608d26144f